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Abstract. Plasmodium falciparum and human immunodeficiency virus (HIV) are both risk factors for low birth
weight (LBW) and maternal anemia, and they may interact to increase risk of adverse pregnancy outcomes. In 2005 and
2006, we followed 831 pregnant women attending antenatal care clinics in southern Malawi through delivery. HIV was
associated with increased risk of LBW (adjusted prevalence ratio [PRadj] = 3.08, 95% confidence interval [CI] = 1.40,
6.79). Having greater than or equal to three episodes of peripheral parasitemia was also associated with increased risk of
LBW (PRadj = 2.68, 95% CI = 1.06, 6.79). Among multigravidae, dual infection resulted in 9.59 (95% CI = 2.51, 36.6)
times the risk of LBW compared with uninfected multigravidae. HIV infection and placental parasitemia were each
associated with increased risk of anemia. Thus, HIV infection and parasitemia are important independent risk factors for
adverse pregnancy outcomes. Among multigravidae, HIV infection and placental parasitemia may interact to produce an
impact greater than the sum of their independent effects.
INTRODUCTION
Malaria is a tremendous public health challenge in Malawi,
with 3.6 million reported cases resulting in almost 8,000 deaths
annually.1 Each year in Malawi, there are approximately
500,000 pregnancies, and all are at risk for malaria.2 For
these women, infection with Plasmodium falciparum para-
sites may result in adverse pregnancy outcomes, including
malaria-associated infant deaths.3,4 These adverse outcomes
may be mediated through placental malaria, a condition
associated with spontaneous abortion, stillbirth, intrauterine
growth retardation, pre-maturity, and severe maternal
anemia.5,6 The latter three conditions can lead to delivery
of an infant with low birth weight (LBW), one of the most
important risk factors for neonatal mortality and develop-
ment impairment.7,8
The prevalence of human immunodeficiency virus (HIV)
infection in Malawi is also high, with an estimated 12% of
antenatal care clinic attendees affected.2 HIV infection has
also been found to be associated with adverse pregnancy
outcomes such as infant mortality and LBW.9,10 The
increased risk of malaria coupled with HIV infection may
interact to result in adverse pregnancy outcomes more pro-
nounced than would be expected with HIV infection or
malaria alone.11 Studies conducted in Malawi, Tanzania, and
Kenya have reported increased risk of neonatal mortality,
maternal anemia, and LBW in the presence of dual infection
by malaria parasites and HIV versus malaria parasitemia or
HIV alone.12–14 However, previous studies have relied on a
cross-sectional design and determined malaria parasitemia
status at single points during pregnancy. In this study, we
evaluate the effects of HIV and malaria parasitemia during
pregnancy on maternal anemia and LBW among a cohort of
pregnant women in Malawi followed from the second trimes-
ter until delivery.
MATERIALS AND METHODS
Study population and data collection procedures. This was
an observational study of pregnant women receiving routine
antenatal care at the Mpemba and Madziabango Health Cen-
ters in a rural area of Blantyre District, Malawi. Between
March of 2005 and February of 2006, healthy pregnant
women in their second trimester attending the antenatal care
clinics at the study sites were invited to participate in the
study. At enrollment, study nurses collected information on
basic demographic characteristics, socioeconomic data, and
malaria prevention activities from participating women.
Women agreeing to voluntary counseling and testing (VCT)
were tested for HIV on site in addition to receiving pre- and
post-test counseling. HIV-infected women and their infants
were given nevirapine according to national guidelines.
Additionally, women found to be infected with HIV were
referred to an antiretroviral treatment program. Women
attending the antenatal care clinics were administered
sulfadoxine-pyrimethamine (SP) for intermittent presump-
tive therapy in pregnancy (IPTp) and treated for clinical
malaria also according to national guidelines.
Women attended visits according to the standard antenatal
care guidelines, with visits scheduled after enrollment occur-
ring at approximately 26, 32, and 36–38 weeks of gestation. At
each visit, a finger prick blood sample was collected for thick
blood film examination for malaria parasites and determina-
tion of hemoglobin level. For women delivering at the health
centers, placental, cord, and peripheral blood films were col-
lected and examined for malaria parasites on site. Placenta
histology was not conducted. Birth weight, measured with
simple spring balances, was also recorded. For women not
delivering at the health centers, an attempt was made to
identify the women and record birth weight within 24 hours
of delivery. It was not possible to follow-up with non-
attendees at home, and home deliveries were only included
when women attended the center for a post-natal visit.
Laboratory procedures. Peripheral malaria parasitemia was
assessed through microscopic examination of thick blood smear
slides on site by trained laboratory technicians after collecting
*Address correspondence to Steven R. Meshnick, Department of
Epidemiology, University of North Carolina Gillings School of
Global Public Health, CB #7435, Chapel Hill, NC 27599. E-mail:
meshnick@unc.edu
29
blood samples from the participating women. Malaria parasites
were quantified against 200 white blood cells (WBCs). Placen-
tal parasitemia was also assessed through thick blood smear.
For quality control purposes, a 10% random sample of slides
was reexamined by the laboratory supervisor at Ntcheu District
Hospital. HIV infection was assessed using two rapid HIV-1
antibody tests: Determine and Unigold. There was 95% (95%
confidence interval = 93.2–97.8%) agreement between the two
tests in identifying HIV-positive women. CD4+ cell counts
were not evaluated. Hemoglobin levels were estimated from
the finger prick blood samples using HemoCue on site at each
visit and post-partum.
Definitions. Parasitemia was defined as the presence of para-
sites in thick blood smears. Parasite density per microliter was
computed assuming 6,000 WBC/mL blood. Among women with
placental parasitemia, mild parasite density was defined as
< 20,000 parasites/mL, and severe parasitemia was defined as
³ 20,000 parasites/mL. Peripheral parasitemia over the follow-up
period was defined as the number of episodes of parasitemia over
the follow-up visits. Because we could not distinguish between
recrudescence and reinfection, measurements of parasitemia
were assumed to be independent across visits. Malaria para-
sitemia at delivery was defined as peripheral and/or placental
parasitemia on delivery. Fever was rarely observed and thus, was
not included in the definition of parasitemia. Anemia was defined
as hemoglobin < 11 g/dL at delivery. HIV infection was defined
as a positive result on two rapid tests: Determine and Unigold.
Discordant results were excluded from analyses. Neonates were
considered as having LBW if they weighed less than 2,500 g. For
the sociodemographic characteristics, unsafe water sources were
defined as unprotected wells, lakes, rivers, or ponds. Low hous-
ing quality was defined as housing with grass roofs and mud or
grass walls with open unscreened windows.
Statistical analysis. Bivariate and multivariate analyses for
dichotomous outcomes were conducted using binomial regres-
sion. When the binomial regression model was unstable, logistic
regression was used. Continuous birth weight and hemoglobin
were analyzed using general linear models.
To assess confounding for dichotomous outcomes, bivariate
analyses with potential confounding variables were performed
for both the outcomes and main exposures. In the case of binary
variables, if the resultant relative risks were less than or equal to
0.7 or greater than or equal to 1.3, they were considered as
potential confounders. The number of potential confounders
included in final models was further narrowed using a change in
estimate approach with a 10% cutoff. Covariate inclusion for
continuous outcomes models mirrored the inclusion of the
binary outcomes models. Interaction effects were assessed
through the inclusion of interaction terms in the models and the
use of the spreadsheet by Andersson and others15 to determine
the relative excess prevalence caused by interaction (REPI). All
analyses were performed using SAS v9.1 (Cary, NC).
Ethical considerations. Informed consent was obtained
from all participating women in Chichewa. The study was
reviewed and approved by the Institutional Review Boards
at the University of North Carolina at Chapel Hill and the
University of Malawi College of Medicine.
RESULTS
The study enrolled 1,496 women; 831 women completed
follow-up until delivery, with 590 delivering at the health
centers. Descriptive characteristics of the study population
are reported in Table 1. On average, participating women
attended two follow-up visits after enrollment. The aver-
age age of the women was 23.4 years (standard deviation
[SD] = 5.4). The average gestational age at enrollment was
23 weeks (SD = 3.6) and ranged between 14 and 28 weeks.
The prevalence of HIV was 13%. The proportion of women
experiencing two or more episodes of malaria over the follow-
up period was 18%. The mean number of visits among
women with one malaria episode over follow-up was 2.9
(SD = 1.1). The mean number of visits among women with
two and three malaria episodes over follow-up was 3.1
(SD = 1.1) and 3.5 (SD = 1.0), respectively. There were no
significant differences in the main exposures and socio-
demographic characteristics between women who were lost
to follow-up and women who completed follow-up. There
was, however, a difference in maternal weight, with women
not lost to follow-up being on average of 0.81 kg heavier
than women lost to follow-up. There were no significant
differences in the main variables among women delivering
at the health centers versus women delivering elsewhere
except for peripheral parasitemia, with women delivering else-
where slightly more likely to have peripheral parasitemia than
women delivering at the health centers (PR = 1.11, 95% CI =
1.06–1.17).
LBW. Information on birth weight was available for
585 women. Among these women, the incidence of LBW was
9%, and mean birth weight was 3,055 g (SD = 478). In bivar-
iate analyses, HIV infection, placental parasite density
³ 20,000/mL, and greater than or equal to three episodes of
peripheral parasitemia over follow-up were strongly associ-
ated with LBW (Table 2). Placental parasitemia (any density)
was marginally associated with LBW in both bivariate and
multivariate analyses. Furthermore, only HIV infection and
greater than or equal to three episodes of peripheral
parasitemia over follow-up were strongly associated with
LBW after adjusting for potential confounders (Table 2).
Additionally, the risk of LBW among primigravidae was
nearly two times the risk among multigravidae after adjusting
for maternal weight, unsafe water source, gravidity, and HIV
status (Table 2).
Multivariate analyses of mean birth weight revealed a 138-g
reduction in birth weight by HIV infection (Table 2). Placen-
tal parasitemia at delivery did not result in a notable reduc-
tion in birth weight; however, the mean difference for
experiencing peripheral parasitemia greater than or equal to
three times over follow-up was large (–163, 95% CI = –351 to
26). Decreasing numbers of SP IPTp doses received were
associated with decreasing birth weight (P < 0.01) (Table 2).
Being primigravid was associated with a 208-g decrease in
mean birth weight (Table 2).
Maternal anemia. Hemoglobin measurements at delivery
were available for 732 women. The prevalence of anemia
(< 11 g Hb/dL) was similar to the prevalence of LBW at 9%.
HIV infection and placental and peripheral parasitemia were
associated with an increased risk of maternal anemia and
reductions in mean hemoglobin, with placental parasitemia
having the strongest effect (Table 3). Maternal anemia risk
varied with the degree of parasite density, with a parasite
density ³ 20,000 parasites/mL resulting in the highest
increased risk and a higher reduction in mean hemoglobin.
Maternal anemia risk was also associated with number of
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parasitemia episodes, with having two or more episodes being
associated with increased anemia risk and significant reduc-
tions in mean hemoglobin. Compared with women who
received greater than or equal to three doses of SP IPTp,
receiving only one dose was associated with an elevated risk
of maternal anemia before adjustment. There were no signif-
icant differences in anemia risk according to doses of SP
received after multivariate adjustment (Table 3).
Interaction between HIV and parasitemia effects. No sig-
nificant interaction effects between HIV and peripheral or
placental parasitemia were found during multivariate anal-
yses for both LBW and maternal anemia when all gravidities
were analyzed together. The overall REPI for LBW was 6.72
(95% CI = –3.65 to 17.08). The REPI indicates the amount of
observed prevalence that is beyond the sum of the indepen-
dent effects of HIV and placental parasitemia. However,
after stratifying by gravidity, the odds of LBW among multi-
gravidae with both HIV infection and placental parasitemia
were 9.6 (95% CI = 2.5–36.6) times as high as the odds among
women with neither infection (Table 4).
Even after stratifying by gravidity, there was no evidence of
interaction for the joint effects of HIV infection and placental
parasitemia on maternal anemia risk (Table 4). However, the
absolute significant reduction in mean hemoglobin compared
with uninfected women was highest among dually infected
multigravidae. Among primigravidae, women with dual infec-
tion had the highest absolute reduction in hemoglobin levels,
but the estimated difference was imprecise (Table 4).
DISCUSSION
In this cohort of pregnant women, HIV infection was asso-
ciated with LBW and maternal anemia. Both peripheral and
placental parasitemia at delivery were associated with mater-
nal anemia and LBW, with a stronger effect observed on
maternal anemia. Additionally, having greater than or equal
to three episodes of parasitemia over follow-up was associ-
ated with increased LBW risk. Among multigravidae, there
was some evidence of superadditive interaction between HIV
infection and placental parasitemia at delivery in their joint
effects on LBW. No interaction effects were observed for
maternal anemia.
LBW. Our finding that HIV infection was associated with
an increased risk of LBW is consistent with many previous
studies (reviewed in ref. 16). The association of placental
parasitemia with LBW risk is also consistent with many pre-
vious studies (reviewed in ref. 2). Although we observed no
effect of peripheral parasitemia at delivery, having greater
than or equal to three episodes of peripheral parasitemia
over follow-up increased LBW risk. This finding is consistent
with the study conducted in the Democratic Republic of
Congo by Landis and others,17 in which having greater than
Table 1
Characteristics of the study population
All enrolled women All women followed until delivery Women delivering at the health centers
N* Percent N Percent N Percent
Overall 1,496 100 831 100 590 100
Age (years)
15–19 368 24.6 227 27.3 162 27.5
20–24 538 36.0 286 34.4 200 33.9
25 590 39.4 318 38.3 228 38.7
Primigravid 370 24.8 235 28.4 170 28.9
Education = 8 years 1,290 86.3 686 82.7 491 83.2
Married 1,371 91.9 757 91.3 535 90.8
Unemployed 789 52.8 433 52.1 316 53.6
Unsafe water source 443 29.6 197 23.7 150 25.4
Low housing quality 345 23.1 199 24.0 132 22.4
Report always using a bed net 344 23.0 203 24.4 139 23.6
Report insecticide impregnation
of the bed net in the past 6 months
297 19.9 182 21.9 123 20.9
Weight (kg; mean ± SD) 1,488 54.7 ± 6.8 828 55.1 ± 6.9 588 55.2 ± 7.0
HIV seropositive 185 13.5 102 13.5 66 12.3
Placental parasitemia – – 111 13.4 93 15.9
Peripheral parasitemia 476 31.8 112 13.5 95 16.2
Number of times parasitemic
over pregnancy
0 838 56 444 53.4 311 52.7
1 438 29.3 237 28.5 166 28.1
2 136 9.1 84 10.1 61 10.3
3 84 5.6 66 7.9 52 8.8
SP doses received
0 85 5.7 34 4.1 26 4.4
1 388 25.9 156 18.8 108 18.3
2 561 37.5 329 39.6 238 40.3
3 462 30.9 312 37.6 218 37.0
Hemoglobin (g/dL; mean ± SD) 1,486 11.0 ± 1.6 732 12.3 ± 1.7 541 12.3 ± 1.7
Hemoglobin < 11 g/dL 345 23.2 65 8.9 47 8.7
Low birth weight (< 2,500 g) – – – – 49 8.7
Birth weight (g; mean ± SD) – – – – 590 3,057 ± 478
*Sums may not add up to total because of missing values. All measurements were taken at enrollment.
SD = standard deviation.
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or equal to three infections was associated with an increased
risk of intrauterine growth retardation. Additionally, another
study conducted in Malawi among a similar population
reported a similar estimate caused by greater than or equal
to two parasitemia episodes on the risk of LBW and mater-
nal anemia.18 In this latter study, parasitemia at delivery was
included in the number of episodes detected, whereas in the
current study, number of episodes excludes parasitemia at
delivery. These results suggest that parasitemia throughout
the gestation period and not only at delivery should be con-
sidered when assessing effect on LBW risk.
In the study conducted in Zimbabwe by Ticconi and
others,19 the risk of LBW among pregnant women with clini-
cal malaria (defined as the presence of malaria parasitemia
and symptoms) was 10 (95% CI = 6.50–15.65) times the risk of
women without malaria. In our study, high parasite density,
defined as over 20,000 parasites/mL, was associated with a 3.5-
fold increase in the risk of LBW, but this increase was not
significant. The smaller effect seen in our study may be
because of the fact that high parasite density was rarely
accompanied by fever. Nevertheless, the two studies suggest
that the risk of LBW may be influenced by the severity of
malaria infection.
Most previous studies of HIV and malaria during preg-
nancy did not report any interaction between HIV infection
and placental parasitemia in the effect on LBW.3–5,19 One
study, however, found that HIV-positive parasitemic women
had 2.5 (95% CI = 1.0–5.9) times the risk of LBW compared
Table 3
Predictors of risk of maternal anemia and mean hemoglobin
Variable
Hb < 11 g/dL n
(%; N = 65)
Hb ³ 11 g/dL n





Adjusted mean hemoglobin (g/dl)
difference (95% CI)
HIV* 17 (27.4) 70 (11.6) 2.36 (1.49–3.74) 2.12 (1.09–4.14) –0.74 (–1.13 to –0.36)
Placental parasitemia at delivery 21 (32.3) 84 (12.6) 2.57 (1.71–3.85) 3.60 (1.95–6.64) –1.07 (–1.44 to –0.70)
Peripheral parasitemia at delivery* 19 (29.2) 90 (13.5) 2.17 (1.42–3.31) 2.84 (1.53–5.28) –1.08 (–1.45 to –0.72)
Parasites density at delivery
(parasites/mL)
0 44 (67.7) 583 (87.4) Reference Reference Reference
0–20,000 17 (26.2) 75 (11.2) 3.00 (1.63–5.52) 3.30 (1.73–6.28) –1.04 (–1.43 to –0.65)
³ 20,000 4 (6.2) 9 (1.4) 5.89 (1.74–19.9) 5.97 (1.58–22.52) –1.26 (–2.21 to –0.32)
Number of times parasitemic
over follow-up†
0 30 (46.2) 366 (54.9) Reference Reference Reference
1 16 (24.6) 187 (28.0) 1.04 (0.56–1.90) 1.07 (0.54–2.13) –0.30 (–0.72 to 0.11)
2 10 (15.4) 66 (9.9) 1.85 (0.86–3.96) 2.27 (1.00–5.16) –0.74 (–1.34 to –0.12)
3+ 9 (13.9) 48 (7.2) 2.29 (1.02–5.11) 2.34 (0.96–5.72) –0.96 (–1.66 to –0.26)
SP doses received†
0 4 (6.2) 29 (4.4) 1.74 (0.56–5.45) 1.44 (0.45–4.63) –0.04 (–0.89 to 0.81)
1 19 (29.2) 118 (17.7) 2.03 (1.04–3.95) 1.50 (0.73–3.07) –0.40 (–0.91 to 0.10)
2 22 (33.9) 268 (40.2) 1.03 (0.55–1.94) 0.99 (0.52–1.90) –0.12 (–0.52 to 0.29)
3+ 20 (30.8) 252 (37.8) Reference Reference Reference
Primigravid 17 (26.2) 179 (27.0) 0.97 (0.63–1.49) 0.88 (0.47–1.67) 0.04 (–0.25 to 0.34)
*Only women with two concordant HIV tests (N = 62 and 602, respectively).
†All parasitemia outcomes and SP doses were entered in separate models. All models were adjusted for maternal weight, water source, gravidity, and HIV status.
CI = confidence interval; Hb = hemoglobin.
Table 2
Predictors of risk of LBW and mean birth weight
Variable
< 2,500 g n
(%; N = 49)
 2,500 g n





Adjusted mean birth weight (g)
difference† (95% CI)
HIV‡ 12 (26.7) 54 (11.5) 2.32 (1.34–4.00) 3.08 (1.40–6.79) −138 (−250 to −26)
Placental parasitemia at delivery 12 (24.5) 75 (14.7) 1.67 (0.98–2.85) 1.79 (0.83–3.84) −36 (−137 to 66)
Peripheral parasitemia at delivery 12 (24.5) 77 (15.0) 1.63 (0.96–2.77) 0.58 (0.27–1.25) −59 (−42 to 159)
Number of times parasitemic
over follow-up
0 23 (46.9) 276 (53.4) Reference Reference Reference
1 13 (26.5) 151 (29.2) 1.03 (0.51–2.10) 0.90 (0.41–1.98) 6 (−110 to 122)
2 2 (4.1) 53 (10.3) 0.45 (0.10–1.98) 0.34 (0.07–1.59) 35 (−136 to 205)
3+ 11 (22.5) 37 (7.2) 3.57 (1.61–7.91) 2.68 (1.06–6.79) −163 (−351 to 26)
Parasite density at delivery
(parasites/mL)
0 37 (75.5) 437 (85.4) Reference Reference Reference
1–20,000 9 (18.4) 69 (13.5) 1.54 (0.71–3.33) 1.53 (0.66–3.56) −53 (−183 to 78)
20,000 3 (6.1) 6 (1.2) 5.91 (1.42–24.6) 3.51 (0.76–6.28) −220 (−727 to 287)
SP doses received
0 4 (8.2) 21 (4.1) 2.60 (0.78–8.62) 2.00 (0.55–7.22) −242 (−498 to 14)
1 10 (20.4) 93 (18.0) 1.47 (0.63–3.43) 0.95 (0.36–2.54) −135 (−281 to 10)
2 21 (42.9) 212 (41.0) 1.35 (0.67–2.73) 1.27 (0.60–2.67) −46 (−162 to 70)
3+ 14 (28.6) 191 (36.9) Reference Reference Reference
Primigravid 20 (41.7) 140 (27.1) 1.54 (1.07–2.21) 1.98 (1.01–3.88) −208 (−290 to −126)
*All parasitemia outcomes and SP doses were entered in separate models. All models were adjusted for material weight, water source, gravidity, and HIV status.
†All models were adjusted for material weight, housing quality, gravidity, and HIV status (only women with concordant results on the two HIV tests were included in analyses).
‡N = 45 and 496, respectively.
CI = confidence interval.
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with aparasitemic HIV-infected women.13 In our study,
among primigravid women, neither infection increased the
risk of LBW in the presence of the other. It should be noted,
however, that the small number of primigravid women may
not have afforded the analysis sufficient power to detect an
effect. Among multigravid women with placental para-
sitemia, HIV-infected women had almost 10 times the risk
of LBW compared with HIV-uninfected parasitemic women.
Although the confidence limit ratio of this estimate was 15,
indicating imprecision, the magnitude of the estimate is
strongly indicative of superadditive interaction. Furthermore,
at the specified a-level of 0.10, the interaction term among
multigravidae reaches statistical significance, further adding
to the evidence of interaction.
Maternal anemia. The result that HIV and peripheral and
placental parasitemia were strong independent risk factors
for maternal anemia both at delivery and over follow-up
corroborates previous literature. In the study by Van Eijk
and others,20 malaria and HIV were associated with a
slightly elevated risk of anemia among all gravidities. In
the study conducted in Malawi by Rogerson and others,21
both placental and peripheral parasitemia were associated
with anemia (peripheral parasitemia: odds ratio = 1.85, 95%
CI = 1.45–2.36; placental parasitemia: odds ratio = 2.0, 95%
CI = 1.5–2.7), where placental parasitemia was determined
through histological examination. Additionally, the finding
that greater than or equal to two episodes of parasitemia
are associated with a doubling of maternal anemia risk has
also been reported in this population.18 In the study
conducted in Kenya by Ayisi and others,13 however, among
primigravidae, only HIV infection was independently asso-
ciated with anemia (defined as Hb < 8 g/dL). Among
multigravidae, no independent effects of HIV and para-
sitemia were detected; however, coinfection was strongly
associated with increased risk of anemia.13 These differ-
ences in results may be caused by the differing definitions
of maternal anemia.
In contrast to the study by Ayisi and others,13 we did not
detect any interaction between HIV and peripheral or pla-
cental parasitemia in their effect on maternal anemia at
delivery among both primigravid and multigravid women.
Although the risk of anemia was highest among dually
infected women, the estimate for the joint effect was not
greater than the additive effects of HIV infection only and
placental parasitemia only. Furthermore, among primi-
gravid women, we found a significant reduction in hemo-
globin levels only among women with placental parasitemia
in the absence of HIV infection. Among multigravidae, we
found no indication of interaction between HIV infection and
placental parasitemia in their effect on mean hemoglobin
levels. These differences in the results regarding maternal ane-
mia risk may be cause by differing distributions of HIV infec-
tion and gravidity in the two study populations. Another
possible reason is the different cutoff values used, with the
study by Ayisi and others13 using a lower cutoff of < 8 g/dL.
However, we would still expect the differences in mean hemo-
globin to corroborate previous results. The more likely
explanation for the difference is the multifactorial nature of
the etiology of anemia. The factors that contribute to ane-
mia in the two populations may be different or where similar,
have differing distributions, thus affecting the impact of both
HIV infection and placental parasitemia on anemia risk and
mean hemoglobin.
Limitations. The interpretation of these results is subject
to some limitations. First, placental parasitemia was deter-
mined through placental blood film instead of histological
examination, a more sensitive method.21–23 However, this
test would have resulted in misclassification that would
have biased the estimates to the null. Second, we did not
have information on CD4+ counts or other clinical mea-
sures of the stage of HIV infection. Given the association
of HIV infection with age, this information may have
influenced the effects of HIV differentially according to
gravidity. Third, birth weight was available for approxi-
mately 70% of the women. Although there were no signifi-
cant differences in HIV status, malaria preventive behaviors,
and demographic variables between women delivering at the
health centers and those women delivering elsewhere, women
delivering at the health centers were more likely to have
peripheral parasitemia. This finding may limit the generaliz-
ability of the results with regard to birth weight to women
delivering at the health centers versus women in the catch-
ment area of the health centers. Fourth, there is a limitation
that concerns the multiple factors contributing to maternal
Table 4
HIV and placental parasitemia interaction effects
Factor
Adjusted prevalence ratio (95% CI)* Adjusted mean differences (95% CI)*
Primigravida, low birth weight
(< 2,500 g)






Neither infection Reference Reference Reference Reference
HIV only 2.52 (0.44–14.47) 2.02 (0.62–6.57) –220 (–614 to 174) –99 (–305 to 106)
Parasitemia only† 1.65 (0.51–5.35) 0.59 (0.08–4.66) –162 (–377 to 53) 127 (–95 to 349)
Dual infection 6.37 (0.46–88.5) 9.59 (2.51–36.6) –174 (–843 to 495) –216 (–559 to 126)
Interaction P value 0.8 0.1 0.4 0.2
Primigravida, Anemia
(Hb < 11 g/L)
Multigravida, Anemia





Neither infection Reference Reference Reference Reference
HIV only 5.42 (1.79–16.40) 3.73 (1.47–9.47) –0.14 (–1.80 to 1.52) –0.89 (–1.51 to –0.28)
Parasitemia only 2.56 (0.27–24.01) 2.87 (1.25–6.60) –1.02 (–1.86 to –0.17) –1.16 (–1.92 to –0.40)
Dual infection 9.03 (0.68–120.09) 5.21 (1.53–17.7) –1.72 (–4.16 to 0.72) –1.68 (–2.82 to –0.54)
Interaction P value 0.8 0.4 0.6 0.5
*All models were adjusted for maternal weight, water source, gravidity, and HIV status.
†Placental parasitemia.
CI = confidence interval.
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anemia. In this study, we did not assess nutritional status
and the presence of other parasitic infections associated
with anemia risk. However, we were able to adjust for vari-
ables linked to anemia, such as socioeconomic factors and
maternal weight.
CONCLUSIONS
This study confirms the deleterious effects of HIV infection
and parasitemia during pregnancy. We found evidence of
interaction between HIV infection and placental parasitemia
in increasing risk of LBW among multigravidae. Contrasting
previous results, we found no evidence of interaction between
HIV infection and placental parasitemia on maternal anemia
risk. These results underscore the need for continued research
to understand the role of HIV in contributing to adverse
pregnancy outcomes in malaria-endemic areas. Furthermore,
the differential effects according to gravidity highlight the
importance of targeted malaria prevention programs to ensure
that the benefits of protective measures, whether through
IPTp or insecticide-treated nets, accrue to all pregnant women.
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